Published ahead of print on July 25, 2003, doi:10.1164/rccm.200301-144OC
Am. J. Respir. Crit. Care Med., Volume 168, Number 10, November 2003, 1167-1173
A more recent version of this article appeared on November 15, 2003
Submitted on February 3, 2003
Accepted on July 23, 2003
Lung Cancer Screening: A Different Paradigm
Annette McWilliams1*, John Mayo2, Sharyn MacDonald2, Jean C leRiche1, Branko Palcic1, Eva Szabo3, and Stephen Lam1
1 British Columbia Cancer Agency, Vancouver, BC, Canada,
2 Radiology, Vancouver General Hospital, Vancouver, BC, Canada,
3 Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
* To whom correspondence should be addressed. E-mail: amcwilli{at}bccancer.bc.ca.
Thoracic computed tomography (CT) is a sensitive method for detecting early lung cancer, but has a high false-positive rate and is not sensitive for detecting central pre-invasive and micro-invasive cancer. Our hypothesis was that automated quantitative image cytometry (AQC) of sputum cells as the first screening method may improve detection rate by identifying individuals at highest risk for lung cancer. Five hundred and sixty one volunteer current or former smokers 50 years of age, with a smoking history of 30 pack/years, were studied. Among these, 423 were found to have sputum atypia defined as 5 cells with abnormal DNA content using AQC. Non-calcified pulmonary nodules were found in 46% (261/561). Of the 14 detected cancers, 13 were detected in subjects with sputum atypia; 9 by CT and 4 CIS/micro-invasive cancers by autofluorescence bronchoscopy. One cancer was detected by CT alone. AQC of sputum cells improved the detection rate of lung cancer from 1.8 % to 3.1%. CT scan alone would have missed 29% of the cancers. This screening paradigm shift has the additional potential of reducing the number of initial CT scans by at least 25% with further savings in follow-up investigations and treatment.
Key words: Lung Neoplasms; Tomography, X-ray computed; Bronchoscopy; Diagnostic Imaging; Cytology
This article has been cited by other articles:

|
 |

|
 |
 
J. R. Jett and D. E. Midthun
Commentary: CT Screening for Lung Cancer--Caveat Emptor
Oncologist,
April 1, 2008;
13(4):
439 - 444.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J.A. Haasbeek, S. Senan, E. F. Smit, M. A. Paul, B. J. Slotman, and F. J. Lagerwaard
Critical Review of Nonsurgical Treatment Options for Stage I Non-Small Cell Lung Cancer
Oncologist,
March 1, 2008;
13(3):
309 - 319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Bach, G. A. Silvestri, M. Hanger, and J. R. Jett
Screening for Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest,
September 1, 2007;
132(3_suppl):
69S - 77S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Gould, J. Fletcher, M. D. Iannettoni, W. R. Lynch, D. E. Midthun, D. P. Naidich, and D. E. Ost
Evaluation of Patients With Pulmonary Nodules: When Is It Lung Cancer?: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest,
September 1, 2007;
132(3_suppl):
108S - 130S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Kennedy, A. McWilliams, E. Edell, T. Sutedja, G. Downie, R. Yung, A. Gazdar, and P. N. Mathur
Bronchial Intraepithelial Neoplasia/Early Central Airways Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest,
September 1, 2007;
132(3_suppl):
221S - 233S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Yuan, J. R. Mayo, J. C. Hogg, P. D. Pare, A. M. McWilliams, S. Lam, and H. O. Coxson
The Effects of Radiation Dose and CT Manufacturer on Measurements of Lung Densitometry
Chest,
August 1, 2007;
132(2):
617 - 623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. Markowitz, A. Miller, J. Miller, A. Manowitz, S. Kieding, L. Sider, and A. Morabia
Ability of Low-Dose Helical CT To Distinguish Between Benign and Malignant Noncalcified Lung Nodules
Chest,
April 1, 2007;
131(4):
1028 - 1034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Loewen, N. Natarajan, D. Tan, E. Nava, D. Klippenstein, M. Mahoney, M. Cummings, and M. Reid
Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment
Thorax,
April 1, 2007;
62(4):
335 - 340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Li, N. W. Todd, Q. Qiu, T. Fan, R. Y. Zhao, W. H. Rodgers, H.-B. Fang, R. L. Katz, S. A. Stass, and F. Jiang
Genetic Deletions in Sputum as Diagnostic Markers for Early Detection of Stage I Non-Small Cell Lung Cancer
Clin. Cancer Res.,
January 15, 2007;
13(2):
482 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res.,
June 15, 2006;
12(12):
3661 - 3697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F V Gleeson
Is screening for lung cancer using low dose spiral CT scanning worthwhile?
Thorax,
January 1, 2006;
61(1):
5 - 7.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Jett
Limitations of Screening for Lung Cancer with Low-Dose Spiral Computed Tomography
Clin. Cancer Res.,
July 1, 2005;
11(13):
4988s - 4992s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Swensen, J. R. Jett, T. E. Hartman, D. E. Midthun, S. J. Mandrekar, S. L. Hillman, A.-M. Sykes, G. L. Aughenbaugh, A. O. Bungum, and K. L. Allen
CT Screening for Lung Cancer: Five-year Prospective Experience
Radiology,
April 1, 2005;
235(1):
259 - 265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lam, J. C. leRiche, A. McWilliams, C. MacAulay, Y. Dyachkova, E. Szabo, J. Mayo, R. Schellenberg, A. Coldman, E. Hawk, et al.
A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium
Clin. Cancer Res.,
October 1, 2004;
10(19):
6502 - 6511.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Kelloff, R. C. Bast Jr., D. S. Coffey, A. V. D'Amico, R. S. Kerbel, J. W. Park, R. W. Ruddon, G. J. S. Rustin, R. L. Schilsky, C. C. Sigman, et al.
Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment: An Update Prologue
Clin. Cancer Res.,
June 1, 2004;
10(11):
3881 - 3884.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2003
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
301 - 313.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. I. Henschke
Medicine on Lung Cancer Screening: A Different Paradigm
Am. J. Respir. Crit. Care Med.,
November 15, 2003;
168(10):
1143 - 1144.
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 American Thoracic Society
|
|
|